UNSPSC 51373454: Codeine/phenylpropanolamine/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373454 Codeine/phenylpropanolamine/promethazine is a Commodity code that in practice encompasses pharmaceutical and medical products—specifically parenteral solutions, controlled substances for correctional and community health settings, and opioid-reversal agents—rather than the single brand-name formulation its nominal code suggests. State and local governments procure under this code primarily through departments of corrections, county health departments, and public health agencies seeking to supply medically necessary pharmaceuticals and medical-grade products to incarcerated individuals, emergency responders, and community health programs. The work involves sourcing and delivery of intravenous nutrition solutions (TPN and PPN), standard IV solutions, naloxone kits, and drug deactivation systems, with stringent delivery-time requirements (same-day or next-day) and mandatory compliance with state licensing, background clearances, and insurance thresholds. Issuers typically impose set-aside and inclusion goals for minority-owned, women-owned, and disadvantaged businesses and require proof of experience in pharmaceutical preparation, patient monitoring, and secure product handling.

Recent activity concentrates in Washington and Florida. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, with a response deadline of October 7, 2026, seeking parenteral products and services to supply eight correctional facilities across three regions, with aspirational small and diverse business goals of 25%, 10%, and 6% for small, minority-owned, and women-owned businesses respectively and an option for DOC to select up to three contractors per region; the initial contract term runs through June 30, 2030. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, though the posted due date of July 26, 2023 appears inconsistent with the June 2026 post date and reflects a data anomaly in the source.